Etravirine in CSF is highly protein bound

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1161-1168

  Nguyen, Anh ^a   Rossi, Steven ^a   Croteau, David ^b   Best, Brookie M ^a,c   Clifford, David ^d   Collier, Ann C ^e   Gelman, Benjamin ^f   Marra, Christina ^e   Mcarthur, Justin ^g   Mccutchan, J Allen ^h   Morgello, Susan ⁱ   Simpson, David ⁱ   Ellis, Ronald J ^b   Grant, Igor ^j   Capparelli, Edmund ^a   Letendre, Scott ^a,h   Abramson, Ian ^a   Al lozi, Muhammad ^a   Atkinson, J Hampton ^a   Fennema notestine, Christine ^a   Gamst, Anthony C ^a   Heaton, Robert K ^a   Marcotte, Thomas D ^a   Smith, Davey M ^a   Taylor, Michael J ^a   Theilmann, Rebecca ^a   Vaida, Florin ^a   Paul woods, Steven ^a   Cushman, Clint ^a   Dawson, Matthew ^a   Franklin, Donald ^a   Jones, Trudy ^a   Lewis, Kristen ^a   Mintz, Letty ^a   Teshome, Mengesha ^a   Toperoff, Will ^a   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Antiretroviral therapy; Central nervous system; CNS; CSF; HIV; Protein binding

Indexed keywords

ALBUMIN; ETRAVIRINE; RADIOLIGAND;

ADULT; ARTICLE; CEREBROSPINAL FLUID; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EUROPEAN AMERICAN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; LIQUID CHROMATOGRAPHY; MALE; TANDEM MASS SPECTROMETRY; TISSUE LEVEL; ULTRACENTRIFUGATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CEREBROSPINAL FLUID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; ISOTOPE LABELING; MALE; MIDDLE AGED; PLASMA; PROTEIN BINDING; PROTEINS; PYRIDAZINES; TANDEM MASS SPECTROMETRY; ULTRACENTRIFUGATION;

EID: 84877141775     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks517     Document Type: Article

References (22)

1. Letendre SL, van den Brande G, Hermes A et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 2007; 45: 1511-7.
2. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-66.
3. Katlama C, Clotet B, Mills A et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15: 1045-52.
4. Minuto JJ, Haubrich R. Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Futur HIV Ther 2008; 2: 525-37.
5. Tibotec Therapeutics. Intelence (Etravirine) Tablets: Full Prescribing Information. Titusville, NJ: Tibotec Therapeutics, 2008.
6. Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
7. Best BM, Koopmans PP, Letendre SL et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 2011; 66: 354-7.
8. Bristol-Myers Squibb. Sustiva (Efavirenz): Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb, 2011.
9. Tashima KT, Caliendo AM, Ahmad M et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180: 862-4.
10. Kakuda TN, Scholler-Gyure M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50: 25-39.
11. Ter Heine R, Rosing H, van Gorp EC et al. Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2009; 49: 393-400.
12. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003; 75: 3019-30.
13. Aweeka FT, Stek A, Best BM et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 2010; 11: 232-8.
14. Zysset T, Hegel A. Comparison of the Beckman TL-100 ultracentrifuge with the Amicon Centrifree Micropartition filters to determine protein-free phenytoin concentrations. Ther Drug Monit 1987; 9: 433-8.
15. Acosta E, Limoli K, Trinh L et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2011. Abstract 633. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Letendre SL, Marquie-Beck J, Capparelli EV et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
17. Croteau D, Rossi SS, Best BM et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother 2013; 68: 684-9.
18. Haas DW, Stone J, Clough LA et al. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther 2000; 68: 367-74.
19. Moberg L, Stahle L, Sonnerborg A. Total and unbound concentrations of efavirenz in cerebrospinal fluid and plasma. In: Abstracts of Thirteenth International AIDS Conference, Durban, South Africa, 2000. Report 37.
20. Tiraboschi JM, Niubo J, Vila A et al. Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother 2012; 67: 1446-8.
21. Couzigou C, Seang S, Morand-Joubert L et al. Efficacy of etravirine for treatment of acute HIV meningoencephalitis. Clin Infect Dis 2009; 48: e62-5.
22. Boffito M, Back DJ, Blaschke TF et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-35.